Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responsesMenglin Wang, Leaf Huang, Michael B. Foote et al.|Nature Biotechnology|2023Cited by 192
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerMargherita Ambrosini, Filippo Pietrantonio, Benoı̂t Rousseau et al.|Annals of Oncology|2024Cited by 73
<i>BRAF</i> mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastasesStéphane Benoist, Nathan Moreno-Lopez, Luca Viganò et al.|British journal of surgery|2019Cited by 42
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signaturesD. Gulhan, Peter J. Park, Vinay Viswanadham et al.|medRxiv|2024Cited by 4
AcSé immunotherapy trials: Anti-PD-1 therapy for adult patients with selected rare cancer typesAurélien Marabelle, Christophe Massard, François Janot et al.|Annals of Oncology|2018Cited by 0